Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F22%3A00076098" target="_blank" >RIV/65269705:_____/22:00076098 - isvavai.cz</a>
Alternative codes found
RIV/00179906:_____/22:10444216
Result on the web
<a href="https://www.nature.com/articles/s41375-022-01528-x" target="_blank" >https://www.nature.com/articles/s41375-022-01528-x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41375-022-01528-x" target="_blank" >10.1038/s41375-022-01528-x</a>

Result language
angličtina
Original language name
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
Original language description
Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2V617F allele burden [1,2,3]. After discontinuing long-term interferon therapy, hematologic responses may persist [4, 5], which is more likely in patients achieving JAK2V617F allele burden <10% before stopping treatment [6]. Allele burden declines gradually during interferon treatment [7]; however, no data from large, prospective, clinical studies of long-term treatment with pegylated alfa interferons are available.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)